Cargando…
Nitazoxanide, a new drug candidate for the treatment of Middle East respiratory syndrome coronavirus
Nitazoxanide is a broad-spectrum antiviral agent undergoing clinical development for treatment of influenza and other viral respiratory infections. Nitazoxanide exhibits in vitro activity against Middle East respiratory syndrome coronavirus (MERS-CoV) and other coronaviruses, inhibiting expression o...
Autor principal: | Rossignol, Jean-François |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
King Saud Bin Abdulaziz University for Health Sciences. Production and hosting by Elsevier Limited.
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7102735/ https://www.ncbi.nlm.nih.gov/pubmed/27095301 http://dx.doi.org/10.1016/j.jiph.2016.04.001 |
Ejemplares similares
-
A Pilot Clinical Trial of Nitazoxanide in the Treatment of Chronic Hepatitis B
por: Rossignol, Jean‐François, et al.
Publicado: (2019) -
Nitazoxanide: A first-in-class broad-spectrum antiviral agent
por: Rossignol, Jean-François
Publicado: (2014) -
The Middle East respiratory syndrome coronavirus()
por: Reina, Jordi, et al.
Publicado: (2015) -
Treatment strategies for Middle East respiratory syndrome coronavirus
por: Modjarrad, Kayvon
Publicado: (2016) -
Heat inactivation of the Middle East respiratory syndrome coronavirus
por: Leclercq, India, et al.
Publicado: (2014)